Development and External Validation of Prognostic Model for 2-Year Survival of Non-Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 2, 2009, Pages 355-362

  Dehing Oberije, Cary ^a   Yu, Shipeng ^b   De Ruysscher, Dirk ^a   Meersschout, Sabine ^c   Van Beek, Karen ^d   Lievens, Yolande ^d   Van Meerbeeck, Jan ^c   De Neve, Wilfried ^c   Rao, Bharat ^b   van der Weide, Hiska ^a   Lambin, Philippe ^a  

^a MAASTRO CLINIC   (Netherlands)

^b SIEMENS CORPORATE RESEARCH   (United States)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Nomogram; Non small cell lung cancer; NSCLC; Prognostic model; Radiotherapy

Indexed keywords

AREA UNDER THE CURVES; CHEMORADIOTHERAPY; CLINICAL DATUM; CROSS VALIDATIONS; DATA SETS; DECISION-MAKING PROCESS; FORCED EXPIRATORY VOLUME IN 1; GROSS TUMOR VOLUMES; LARGE GROUPS; LEAVE ONE OUTS; MULTIVARIATE MODELS; NON-SMALL-CELL LUNG CANCER; NSCLC; POSITIVE LYMPH NODES; PREDICTION MODELS; PROGNOSTIC MODEL; RECEIVER OPERATING CHARACTERISTICS; RISK SCORES; TNM STAGES; WORLD HEALTH ORGANIZATIONS;

CHEMOTHERAPY; HEALTH RISKS; NOMOGRAMS; PATIENT MONITORING; RADIOTHERAPY;

BIOLOGICAL ORGANS;

CARBOPLATIN; GEMCITABINE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MODEL; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SUPPORT VECTOR MACHINE; SURVIVAL TIME; TUMOR VOLUME; VALIDATION PROCESS;

AGED; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MODELS, STATISTICAL; NOMOGRAMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR BURDEN;

EID: 67349199539     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.08.052     Document Type: Article

References (40)

1. Vulto A., Louwman M., Rodrigus P., et al. Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands, 1988-2002. Radiother Oncol 78 (2006) 131-137
2. Schrevens L., Lorent N., Dooms C., et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 9 (2004) 633-643
3. Dehing-Oberije C., De Ruysscher D., van der Weide H., et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1039-1044
4. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122 (2002) 1037-1057
5. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22 (2004) 330-353
6. Firat S., Byhardt R.W., Gore E., and Radiation Therapy Oncology Group. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 54 (2002) 357-364
7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2 (2000) CD002139
8. Solan M.J., and Werner-Wasik M. Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 21 (2003) 64-73
9. Zhao L., West B.T., Hayman J.A., et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 68 (2007) 103-110
10. Werner-Wasik M., Swann R.S., Bradley J., et al. Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70 (2008) 385-390
11. Bradley J.D., Ieumwananonthachai N., Purdy J.A., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52 (2002) 49-57
12. Basaki K., Abe Y., Aoki M., et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume. Int J Radiat Oncol Biol Phys 64 (2006) 449-454
13. Ball D., Smith J., Wirth A., et al. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 54 (2002) 1007-1013
14. International Commission on Radiation Units and Measurements. ICRU report 50: Prescribing, recording, and reporting photon beam therapy (1993), International Commission on Radiation Units and Measurements, Bethesda
15. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
16. Senan S., De Ruysscher D., Giraud P., et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
17. Maastricht Radiation Oncology, The Netherlands. Radiotherapy for NSCLC to an individualized MLD (BRONC MLD).ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT00573040, NLM identifier: NCT00573040. Accessed January 22 2008.
18. van Baardwijk A., Bosmans G., Boersma L., et al. Individualized radical radiotherapy of non-small-cell lung cancer (NSCLC) based on normal tissue dose constraints: A feasibility study. Int J Radiat Oncol Biol Phys 71 (2008) 1394-1401
19. Fowler J.F., Tome W.A., Fenwick J.D., et al. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60 (2004) 1241-1256
20. Cristianini N., and Shawe-Taylor J. An introduction to support vector machines and other kernel-based learning methods (2000), Cambridge University Press, Cambridge
21. Platt J.C. Probabilities for SV machines. In: Smola A.J., Bartlett P., Scholkopf B., et al. (Eds). Advances in large margin classifiers (2000), MIT Press, Cambridge
22. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48 (2000) 1475-1482
23. Komaki R., Scott C.B., Byhardt R., et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four Radiation Therapy Oncology Group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 42 (1998) 263-267
24. Blanchon F., Grivaux M., Asselain B., et al. 4-Year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index. Lancet Oncol 7 (2006) 829-836
25. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., et al. for the Leuven Lung Cancer Group. Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases. Ann Thorac Surg 63 (1997) 1441-1450
26. Davies A., Tan C., Paschalides C., et al. FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients. Lung Cancer 55 (2007) 75-78
27. van Baardwijk A., Dooms C., van Suylen R.J., et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43 (2007) 1392-1398
28. Vesselle H., Freeman J.D., Wiens L., et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 13 (2007) 3255-3263
29. Öllers M., Bosmans G., van Baardwijk A., et al. The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiother Oncol 87 (2008) 142-146
30. Ademuyiwa F.O., Johnson C.S., White A.S., et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer 8 (2007) 478-482
31. Birim O., Kappetein A.P., Waleboer M., et al. Long-term survival after non-small cell lung cancer surgery: Development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg 132 (2006) 491-498
32. Mandrekar S.J., Schild S.E., Hillman S.L., et al. A prognostic model for advanced stage nonsmall cell lung cancer: Pooled analysis of North Central Cancer Treatment Group trials. Cancer 107 (2006) 781-792
33. Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 44 (1997) 9-15
34. Wigren T., Oksanen H., and Kellokumpu-Lehtinen P. A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 123 (1997) 259-266
35. Steyerberg E.W., Bleeker S.E., Moll H.A., et al. Internal and external validation of predictive models: A simulation study of bias and precision in small samples. J Clin Epidemiol 56 (2003) 441-447
36. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
37. Hanai T., Yatabe Y., Nakayama Y., et al. Prognostic models in patients with non-small-cell lung cancer using artificial neural networks in comparison with logistic regression. Cancer Sci 94 (2003) 473-477
38. Alberts W.M. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 1S-19S
39. Shepherd F.A., and Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2 Suppl. 2 (2007) S68-S76
40. Chung C.H., Levy S., Chaurand P., et al. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 61 (2007) 1-25